Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: Summary of NICE guidance

BMJ

Volumn 337, Issue 7672, 2008, Pages 751-753

  Kendall, Tim ^a,b,c   Taylor, Eric ^d   Perez, Alejandra ^e   Taylor, Clare ^a  

^a National Collaborating Centre for Mental Health   (United Kingdom)

^b ROYAL COLLEGE OF PSYCHIATRISTS   (United Kingdom)

^c SHEFFIELD HEALTH AND SOCIAL CARE NHS FOUNDATION TRUST   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER; CHILD; COGNITIVE THERAPY; DIET; EDUCATIONAL STATUS; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HUMAN; MEDICAL EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; ARTICLE; COUNSELING; EDUCATION; METHODOLOGY; PARENT; PRESCHOOL CHILD; TEACHING;

ADRENERGIC RECEPTOR AFFECTING AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE; PROPYLAMINE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; COUNSELING; DIET; HUMANS; METHYLPHENIDATE; PARENTS; PRACTICE GUIDELINES AS TOPIC; PROPYLAMINES; TEACHING;

EID: 52649104413     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a1239     Document Type: Short Survey

References (10)

1. Moffit TE. Juvenile delinquency and attention deficit disorder: boys' developmental trajectories from age 3 to 15. Child Development 1990;61:893-910.
2. Taylor E, Chadwick O, Heptinstall E, Danckaerts M. Hyperactivity and conduct problems as risk factors for adolescent development. J Am Acad Child Adolesc Psychiatry 1996;35:1213-26.
3. Biederman J, Monuteaux MC, Micke E, Spencer T, Wilens TE, Silva JM, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006;36:167-79.
4. National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Technology Appraisal 98. www.nice.org.uk/TA98
5. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. 2008. (Clinical guideline 72) www.nice.org.uk/CG72
6. McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, et al. Trends in prescribing prevalence and cessation of ADHD drug treatment among adolescents and young adults in the United Kingdom. Br J Psychiatry (in press).
7. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983;40:1228-31.
8. Department of Health. National service framework for children, young people and maternity services. The mental health and psychological well-being of children and young people. London: Stationery Office, 2004.
9. Sayal K, Goodman R, Ford, T. Barriers to the identification of children with attention deficit/hyperactivity disorder. J Child Psychol Psychiatry 2006;47:744-50.
10. Cox ER, Motheral BR, Henderson RR, Mager D. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics 2003;111:237-43.